Trials / Completed
CompletedNCT00783653
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | 25 mg or 37,5 mg daily dose until DLT |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2013-07-01
- First posted
- 2008-11-03
- Last updated
- 2020-02-25
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00783653. Inclusion in this directory is not an endorsement.